ORIC Pharmaceuticals Inc logo

ORIC

ORIC Pharmaceuticals Inc

$4.43

Earnings Summary

Revenue
$0Mn
Net Profits
$-23.16Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

ORIC Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, ORIC Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

ORIC Pharmaceuticals Inc’s net profit fell -31322.06% since last year same period to $-23.16Mn in the Q1 2022. On a quarterly growth basis, ORIC Pharmaceuticals Inc has generated 41.04% jump in its net profits since last 3-months.

Net Profit Margins:

ORIC Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, ORIC Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ORIC Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.6
EPS Estimate Current Year
-0.6

Highlights

EPS Estimate Current Quarter:

ORIC Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.6 - a -5.26% fall from last quarter’s estimates.

EPS Estimate Current Year:

ORIC Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.6.

Key Ratios

Key ratios of the ORIC Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.59
Return on Assets (ROA)
-0.2
Return on Equity (ROE)
-0.34
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

ORIC Pharmaceuticals Inc’s earning per share (EPS) fell -31.11% since last year same period to -0.59 in the Q1 2022. This indicates that the ORIC Pharmaceuticals Inc has generated -31.11% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ORIC Pharmaceuticals Inc’s return on assets (ROA) stands at -0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ORIC Pharmaceuticals Inc’s return on equity (ROE) stands at -0.34.

Dividend Per Share (DPS):

ORIC Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.57
-0.59
-3.51%

Company Information

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC's other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.

Organisation
ORIC Pharmaceuticals Inc
Headquarters
South San Francisco, California, US
Employees
61
Industry
Health Technology
CEO
Jacob Chacko